The Drug Controller General of India (DCGI) on Wednesday granted permission to Hyderabad-based Biological E Limited to conduct Phase 2 and 3 clinical trials for its anti-COVID shots called Corbevax on children between 5 and 18 years of age with certain conditions, sources told ANI.
The trial will be conducted in ten locations.
The permission has been given to Biological E after the recommendation from the Subject Expert Committee.
Meanwhile, Zydus Cadila's needle-free COVID-19 vaccine ZyCoV-D has already received emergency use authorisation (EUA) to inoculate children in the age group of 12-18. It is expected to be administered from the first week of October.
The trials of Bharat Biotech's Covaxin COVID-19 vaccine for phases 2 & 3 for children are on, and its result is expected in September.
It is to be noted that the government has made an advance payment of Rs 1,500 crore to Biological E for 30 crore vaccines.
Biological E, Bharat Biotech Have 250 Million Covid Vaccine Stockpile: Report Hyderabad-Based Biological E Gets Approval For Pneumococcal Conjugate Vaccine Corbevax Approved As Booster Dose For Adults Vaccinated With Covaxin, Covishield Pics: Rahul Gandhi's Family Lunch At Iconic Delhi Restaurant Is Safe Car Enough? Volvo Crash That Killed CEO, Family Sparks Big Question "Nothing Short Of Nightmare": Woman Misses Life Event, Slams Air India Can Elon Musk Become US President? Donald Trump Says... Public Sector Hydropower Company Hiring For 118 Posts, Check Details Delhi's Air Quality Turns 'Severe' Despite GRAP-4 Restrictions Track Latest News Live on NDTV.com and get news updates from India and around the world.